Drug Type Antibody drug conjugate (ADC) |
Synonyms LBL 061, LBL061 |
Target |
Action modulators |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators), PDL1 modulators(Programmed death-ligand 1 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Nasopharyngeal Carcinoma | Preclinical | China | 01 Jun 2025 | |
| Non-Small Cell Lung Cancer | Preclinical | China | 01 Jun 2025 | |
| Squamous Cell Carcinoma of Head and Neck | Preclinical | China | 01 Jun 2025 |






